Dr. Ying Sun is a Professor of Radiation Oncology and vice president at Sun Yat-sen University Cancer Center, Guangzhou, China. 

The main research interest of Prof. Sun is personalized and precision treatment of nasopharyngeal carcinoma (NPC), particularly interests include artificial intelligence-assisted radiotherapy of NPC, big data-driven risk stratification and personalized treatment of non-metastatic NPC, and translational research focused on developing prognostic and predictive markers and underlying the mechanisms of treatment resistance of NPC. She has established a recommendation for contouring methods and atlas of organs at risk for NPC patients, which has been adopted by international guidelines. She has also developed the first real world big-data intelligence platform for NPC research and AI tool for automated contouring of gross tumor volume for NPC on MRI.

As the first author and/or corresponding author, Prof. Sun has published over 60 papers in prestigious, international peer-reviewed journals, such as N Engl J Med, Lancet, Lancet Oncol, Nat Commun, Cell Death Differ, Clin Cancer Res, Cancer Res, Radiology, Cancer, Int J Radiat Oncol Biol Phys and Radiother Oncol. She also serves as a reviewer and member of the editorial boards of many peer-reviewed journals. During 2020 and 2021, she has been honored as a “Chang Jiang Scholar of Ministry of Education”, “the new Century Millions talent project national candidate”, and “Youth scientific and technological innovation leader of the Talent Promotion Program of the Chinese Ministry of Science and Technology”. In 2018, she was honored as “Distinguished Professor of Guangdong Province Universities and Colleges Pearl River Scholar”. In 2009, and 2015 she received the “National Science and Technology Progress Award” as a major participant. 

Additionally, she is the vice-chairman of the First Youth Council of the Chinese Anticancer Association, the vice Chairman of the Chinese Society of Clinical Oncology-Nasopharyngeal Cancer Special Committee, and the vice Chairman of China Anti-Cancer Association-Big data and Real World Research Committee.

Individualized and precise treatment of nasopharyngeal carcinoma.

Bachelor of Medical Imaging, Harbin Medical University, Harbin, China, 1992-1997

Master and Doctorate degree of Imaging and Nuclear Medicine, Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 1997-2012.

Visiting Scholar, William Beaumont Hospital, Michigan, US, 2012-2013.

[1] Zhang Y#, Chen L#, Hu GQ#, Zhang N#, Zhu XD#, Yang KY#, Jin F#, Shi M#, Chen YP#, ..., Chua MLK*, Xie FY*, Sun Y*, Ma J*. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New Engl J Med, 2019.09.19;381(12):1124-1135. ( IF 91.245)

[2] Chen YP#, Liu X#, Zhou Q#, Yang KY#, Jin F#, Zhu XD#,Shi M#, Hu GQ#, Hu WH#, ..., Tang LL*, Xie FY*, Sun Y* , Ma J*. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021 Jun 4;S0140-6736(21)01123-5. ( IF 79.321)

[3] Chen YP#, Chan ATC#, Le QT#, Blanchard P#, Sun Y*, Ma J*. Nasopharyngeal carcinoma, Lancet, 2019 Jul 6;394(10192):64-80. ( IF 79.321)

[4] Chen YP#,, ..., Sun Y*, Ma J*.Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021 Mar 1;39(7):840-859. ( IF 44.544)

[5] Sun Y#, Li WF#, Chen NY#, Zhang N#,  Hu GQ#, Xie FY#, Sun Y#, ..., Ma J*. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol, 2016; 17(11): 1509~1520. (IF 41.316)

[6] Chen YP#, Lv JW#, Mao YP#, Li XM#, Li JY#, Wang YQ#, ..., Sun Y*, Liu N*, Ma J*. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer. 2021 Jan 11;20(1):14. (IF 27.401)

[7] Zhou GQ#, Wu CF#, Deng B#, ..., Liang JH*, Sun Y*. An optimal posttreatment surveillance strategy for cancer survivors based on an individualized risk-based approach. Nat Commun, 2020 Aug 3;11(1):3872 (IF 14.919)

[8] Lv JW#, Chen YP#, Zhou GQ#, Qi ZY#, ..., Chua MLK*, Sun Y*. Liquid biopsy tracking during sequential chemoradiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun, 2019 Sep 2,10:3941. (IF 14.919)

[9] Lei Y#, LiYQ#, Jiang W#, Hong XH#, Ge WX#, Zhang Y#, n Hu WH#,..., Tang LL*, Sun Y*, Liu N*, Ma J*,A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. J Natl Cancer Inst.2021 Apr 6;113(4):471-480. (IF 13.506)

[10] Lv JW#, Zheng ZQ#, Wang ZX#, Zhou GQ#, ..., Chen YP*, Sun Y*. Pan-cancer Genomic Analyses Reveal Prognostic and Immunogenic Features of the Tumor Melatonergic Microenvironment Across 14 Solid Cancer Types. J Pineal Res, 2019 Apr;66(3). (IF13.007)




Updated November 2021